Association between musculoskeletal ultrasonography and bone remodelling markers and its role in disease monitoring of gout and hyperuricaemia

To evaluate associations between bone destruction markers and musculoskeletal ultrasonography (MU) findings in patients with gout and hyperuricaemia and clarify the role of MU in treatment responsiveness. One-hundred and fifty patients with gout and 100 patients with hyperuricaemia were divided into...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2020-09, Vol.38 (5), p.896-902
Hauptverfasser: Zou, Yadan, Fei, Yanan, Gao, Hui, Xie, Lin-Feng, Zhong, Yu-Chao, Yang, Qun-Zhi, Wang, Da-Li, Zhang, Xue-Wu
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 902
container_issue 5
container_start_page 896
container_title Clinical and experimental rheumatology
container_volume 38
creator Zou, Yadan
Fei, Yanan
Gao, Hui
Xie, Lin-Feng
Zhong, Yu-Chao
Yang, Qun-Zhi
Wang, Da-Li
Zhang, Xue-Wu
description To evaluate associations between bone destruction markers and musculoskeletal ultrasonography (MU) findings in patients with gout and hyperuricaemia and clarify the role of MU in treatment responsiveness. One-hundred and fifty patients with gout and 100 patients with hyperuricaemia were divided into five groups according to MU manifestations. Circulating Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand (RANKL) levels were measured. Thirty patients from the gout group and 10 from the hyperuricaemia group, were treated for 1 year with urate-lowering therapy (ULT). Patients with gout and tophus and/or bone erosion had the highest DKK-1 and RANKL levels. Patients with gout and MU-evidenced aggregates and/or double-contour signs had higher DKK-1 and RANKL levels than the normal MU group (p
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2329737584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2329737584</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-7049fd4acfdac6abf422b53dccc5724402035fbdbe2c0820e4d8ea90f0df72c33</originalsourceid><addsrcrecordid>eNo1kMtKAzEYhWeh2Fp9BcnSzUCaTOayLMUbFNwouBv-Sf60sZlkzAXpS_jMVq2rszgfB75zVswp71jZivptVlzG-E4pq0XdXBQzvmxF24l2XnytYvTSQDLekQHTJ6IjY44yWx_3aDGBJdmmANE7vw0w7Q4EnCKDd0gCjl6htcZtyQhhjyH-liZFErxFYhxRJiJEJKN3Jvnwg3pNtj6nX3R3mDDkYCTgaOCqONdgI16fclG83t-9rB_LzfPD03q1KSe2XKayoVWnVQVSK5A1DLpibBBcSSlFw6qKMsqFHtSATNKWUaxUi9BRTZVumOR8Udz-7U7Bf2SMqR9NlEcTcOhz7BlnXcMb0VZH9OaE5mFE1U_BHFUP_f-H_BscKnIE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2329737584</pqid></control><display><type>article</type><title>Association between musculoskeletal ultrasonography and bone remodelling markers and its role in disease monitoring of gout and hyperuricaemia</title><source>Alma/SFX Local Collection</source><creator>Zou, Yadan ; Fei, Yanan ; Gao, Hui ; Xie, Lin-Feng ; Zhong, Yu-Chao ; Yang, Qun-Zhi ; Wang, Da-Li ; Zhang, Xue-Wu</creator><creatorcontrib>Zou, Yadan ; Fei, Yanan ; Gao, Hui ; Xie, Lin-Feng ; Zhong, Yu-Chao ; Yang, Qun-Zhi ; Wang, Da-Li ; Zhang, Xue-Wu</creatorcontrib><description><![CDATA[To evaluate associations between bone destruction markers and musculoskeletal ultrasonography (MU) findings in patients with gout and hyperuricaemia and clarify the role of MU in treatment responsiveness. One-hundred and fifty patients with gout and 100 patients with hyperuricaemia were divided into five groups according to MU manifestations. Circulating Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand (RANKL) levels were measured. Thirty patients from the gout group and 10 from the hyperuricaemia group, were treated for 1 year with urate-lowering therapy (ULT). Patients with gout and tophus and/or bone erosion had the highest DKK-1 and RANKL levels. Patients with gout and MU-evidenced aggregates and/or double-contour signs had higher DKK-1 and RANKL levels than the normal MU group (p<0.001). Patients with hyperuricaemia and abnormal MU findings had significantly higher DKK-1 and RANKL levels than those with normal MU findings. DKK-1 and RANKL levels positively correlated with disease duration in patients with gout (r=0.430, p<0.001; r=0.359, p<0.001, respectively) and hyperuricaemia (r=0.446, p<0.001; r=0.379, p<0.001, respectively). After ULT, MU abnormalities disappeared in 12 and 8 patients with gout and hyperuricaemia, respectively. The largest tophus diameter decreased in patients with gout (t=6.092, p<0.001). DKK-1 and RANKL concentrations significantly decreased in all patients. Lower serum urate levels corresponded with higher ratios of normal MU features in all patients. In patients with gout and hyperuricaemia, MU manifestations were associated with DKK-1 and RANKL levels and were ameliorated after ULT. Thus, MU could be a useful tool in assessing bone remodelling and monitoring disease responsiveness.]]></description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 31858958</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and experimental rheumatology, 2020-09, Vol.38 (5), p.896-902</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31858958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zou, Yadan</creatorcontrib><creatorcontrib>Fei, Yanan</creatorcontrib><creatorcontrib>Gao, Hui</creatorcontrib><creatorcontrib>Xie, Lin-Feng</creatorcontrib><creatorcontrib>Zhong, Yu-Chao</creatorcontrib><creatorcontrib>Yang, Qun-Zhi</creatorcontrib><creatorcontrib>Wang, Da-Li</creatorcontrib><creatorcontrib>Zhang, Xue-Wu</creatorcontrib><title>Association between musculoskeletal ultrasonography and bone remodelling markers and its role in disease monitoring of gout and hyperuricaemia</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description><![CDATA[To evaluate associations between bone destruction markers and musculoskeletal ultrasonography (MU) findings in patients with gout and hyperuricaemia and clarify the role of MU in treatment responsiveness. One-hundred and fifty patients with gout and 100 patients with hyperuricaemia were divided into five groups according to MU manifestations. Circulating Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand (RANKL) levels were measured. Thirty patients from the gout group and 10 from the hyperuricaemia group, were treated for 1 year with urate-lowering therapy (ULT). Patients with gout and tophus and/or bone erosion had the highest DKK-1 and RANKL levels. Patients with gout and MU-evidenced aggregates and/or double-contour signs had higher DKK-1 and RANKL levels than the normal MU group (p<0.001). Patients with hyperuricaemia and abnormal MU findings had significantly higher DKK-1 and RANKL levels than those with normal MU findings. DKK-1 and RANKL levels positively correlated with disease duration in patients with gout (r=0.430, p<0.001; r=0.359, p<0.001, respectively) and hyperuricaemia (r=0.446, p<0.001; r=0.379, p<0.001, respectively). After ULT, MU abnormalities disappeared in 12 and 8 patients with gout and hyperuricaemia, respectively. The largest tophus diameter decreased in patients with gout (t=6.092, p<0.001). DKK-1 and RANKL concentrations significantly decreased in all patients. Lower serum urate levels corresponded with higher ratios of normal MU features in all patients. In patients with gout and hyperuricaemia, MU manifestations were associated with DKK-1 and RANKL levels and were ameliorated after ULT. Thus, MU could be a useful tool in assessing bone remodelling and monitoring disease responsiveness.]]></description><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo1kMtKAzEYhWeh2Fp9BcnSzUCaTOayLMUbFNwouBv-Sf60sZlkzAXpS_jMVq2rszgfB75zVswp71jZivptVlzG-E4pq0XdXBQzvmxF24l2XnytYvTSQDLekQHTJ6IjY44yWx_3aDGBJdmmANE7vw0w7Q4EnCKDd0gCjl6htcZtyQhhjyH-liZFErxFYhxRJiJEJKN3Jvnwg3pNtj6nX3R3mDDkYCTgaOCqONdgI16fclG83t-9rB_LzfPD03q1KSe2XKayoVWnVQVSK5A1DLpibBBcSSlFw6qKMsqFHtSATNKWUaxUi9BRTZVumOR8Udz-7U7Bf2SMqR9NlEcTcOhz7BlnXcMb0VZH9OaE5mFE1U_BHFUP_f-H_BscKnIE</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Zou, Yadan</creator><creator>Fei, Yanan</creator><creator>Gao, Hui</creator><creator>Xie, Lin-Feng</creator><creator>Zhong, Yu-Chao</creator><creator>Yang, Qun-Zhi</creator><creator>Wang, Da-Li</creator><creator>Zhang, Xue-Wu</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>Association between musculoskeletal ultrasonography and bone remodelling markers and its role in disease monitoring of gout and hyperuricaemia</title><author>Zou, Yadan ; Fei, Yanan ; Gao, Hui ; Xie, Lin-Feng ; Zhong, Yu-Chao ; Yang, Qun-Zhi ; Wang, Da-Li ; Zhang, Xue-Wu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-7049fd4acfdac6abf422b53dccc5724402035fbdbe2c0820e4d8ea90f0df72c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zou, Yadan</creatorcontrib><creatorcontrib>Fei, Yanan</creatorcontrib><creatorcontrib>Gao, Hui</creatorcontrib><creatorcontrib>Xie, Lin-Feng</creatorcontrib><creatorcontrib>Zhong, Yu-Chao</creatorcontrib><creatorcontrib>Yang, Qun-Zhi</creatorcontrib><creatorcontrib>Wang, Da-Li</creatorcontrib><creatorcontrib>Zhang, Xue-Wu</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zou, Yadan</au><au>Fei, Yanan</au><au>Gao, Hui</au><au>Xie, Lin-Feng</au><au>Zhong, Yu-Chao</au><au>Yang, Qun-Zhi</au><au>Wang, Da-Li</au><au>Zhang, Xue-Wu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between musculoskeletal ultrasonography and bone remodelling markers and its role in disease monitoring of gout and hyperuricaemia</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>38</volume><issue>5</issue><spage>896</spage><epage>902</epage><pages>896-902</pages><issn>0392-856X</issn><abstract><![CDATA[To evaluate associations between bone destruction markers and musculoskeletal ultrasonography (MU) findings in patients with gout and hyperuricaemia and clarify the role of MU in treatment responsiveness. One-hundred and fifty patients with gout and 100 patients with hyperuricaemia were divided into five groups according to MU manifestations. Circulating Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand (RANKL) levels were measured. Thirty patients from the gout group and 10 from the hyperuricaemia group, were treated for 1 year with urate-lowering therapy (ULT). Patients with gout and tophus and/or bone erosion had the highest DKK-1 and RANKL levels. Patients with gout and MU-evidenced aggregates and/or double-contour signs had higher DKK-1 and RANKL levels than the normal MU group (p<0.001). Patients with hyperuricaemia and abnormal MU findings had significantly higher DKK-1 and RANKL levels than those with normal MU findings. DKK-1 and RANKL levels positively correlated with disease duration in patients with gout (r=0.430, p<0.001; r=0.359, p<0.001, respectively) and hyperuricaemia (r=0.446, p<0.001; r=0.379, p<0.001, respectively). After ULT, MU abnormalities disappeared in 12 and 8 patients with gout and hyperuricaemia, respectively. The largest tophus diameter decreased in patients with gout (t=6.092, p<0.001). DKK-1 and RANKL concentrations significantly decreased in all patients. Lower serum urate levels corresponded with higher ratios of normal MU features in all patients. In patients with gout and hyperuricaemia, MU manifestations were associated with DKK-1 and RANKL levels and were ameliorated after ULT. Thus, MU could be a useful tool in assessing bone remodelling and monitoring disease responsiveness.]]></abstract><cop>Italy</cop><pmid>31858958</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2020-09, Vol.38 (5), p.896-902
issn 0392-856X
language eng
recordid cdi_proquest_miscellaneous_2329737584
source Alma/SFX Local Collection
title Association between musculoskeletal ultrasonography and bone remodelling markers and its role in disease monitoring of gout and hyperuricaemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T05%3A18%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20musculoskeletal%20ultrasonography%20and%20bone%20remodelling%20markers%20and%20its%20role%20in%20disease%20monitoring%20of%20gout%20and%20hyperuricaemia&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Zou,%20Yadan&rft.date=2020-09-01&rft.volume=38&rft.issue=5&rft.spage=896&rft.epage=902&rft.pages=896-902&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2329737584%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2329737584&rft_id=info:pmid/31858958&rfr_iscdi=true